HYPR — Hyperfine, Inc.

Summary of HYPR Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $3.9 million, an 83% increase year-over-year from $2.1 million in Q1 2025.
• Gross Margin: 51%, up from 41.3% in the prior year, marking the third consecutive quarter above 50%.
• Net Loss: $8.6 million ($0.09 per share), an improvement from a net loss of $9.4 million ($0.12 per share) in Q1 2025.
• Cash Burn: $8.8 million, a reduction of $1.3 million (13%) compared to $10.1 million in Q1 2025.
• Cash Position: $40.8 million in cash and cash equivalents, including a $15 million tranche from a new long-term debt facility.

2. Strategic Updates and Business Highlights

• Product Launches: Successfully launched the next generation subsystem and advanced DWI Optive AI software, achieving CE and UKCA marks.
• Market Expansion: Increased enrollment in the contrast PMR study, with over 50% of the target achieved.
• Business Verticals: Strong performance across hospitals, health systems, and neurology offices, with significant interest from critical care and emergency departments.
• International Growth: Initial systems launched in India and positive reception for the AI software in Europe.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be between $20 million and $22 million, representing a 55% year-over-year growth at the midpoint.
• Gross Margin Expectations: Anticipated to remain between 50% and 55%, with improvements expected in the second half of the year.
• Cash Burn Projections: Estimated total cash burn for 2026 to be between $26 million and $28 million, reflecting a 10% year-over-year decline.
• Long-term Outlook: Healthy cash runway extending into 2028, supported by disciplined spending and a strong balance sheet.

4. Bad News, Challenges, or Points of Concern

• Sales Cycle Length: The transition to multi-unit sales within Integrated Delivery Networks (IDNs) involves longer sales cycles and more complex procurement processes.
• Cash Burn Management: Although there was a reduction in cash burn, the company remains focused on controlling expenses amidst ongoing investments in growth initiatives.
• Market Competition: Potential competitive pressures from traditional high-field MRI systems, despite the advantages of being helium-free and portable.

5. Notable Q&A Insights

• IDN Sales Dynamics: Conversations with IDNs are primarily at the initial placement stage, with longer timelines for standardization across multiple sites.
• Office Market Adoption: Larger practices are showing strong interest due to higher patient volumes and the economic justification of the subsystem's utility.
• Helium Shortage Impact: The helium shortage has not significantly affected customer interactions, as Hyperfine's systems do not require helium.
• Contrast PMR Study: There is excitement for the potential of gadolinium contrast to enhance adoption, but no current purchases have been delayed due to its absence.
• Expansion into New Care Sites: Interest from surgical teams for using the subsystem in operating rooms is growing, with plans to develop a strategy for this market by the end of 2026.

Overall, Hyperfine reported a strong start to 2026, with significant revenue growth, improved margins, and strategic advancements, while also navigating challenges related to longer sales cycles and competitive dynamics.